Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old

Year: 2018

Type: article

Abstract: was higher on than in patients off anti-TB therapy. Reduced efavirenz clearance by first-line anti-TB therapy at the population level led to similar PK parameters in HIV-infected children with and without TB coinfection. Our findings do not support modification of efavirenz weight-band dosing guidelines based on TB coinfection status in children. (The study was registered with ClinicalTrials.gov under registration number NCT01704144.).

Source: Antimicrobial Agents and Chemotherapy

DOI: 10.1128/aac.01657-18

Authors: Awewura Kwara, Hongmei Yang, Sampson Antwi, Anthony Enimil, Fizza S. Gillani, Albert Dompreh, Antoinette Ortsin, Theresa Opoku, Dennis Bosomtwe, Anima Sarfo, Lubbe Wiesner, Jennifer Norman, Wael A. Alghamdi, Taimour Langaee, Charles A. Peloquin, Michael H. Court, David J. Greenblatt

Institutions: University of Florida, University of Rochester Medicine, University of Rochester, Komfo Anokye Teaching Hospital, Kwame Nkrumah University of Science and Technology, Miriam Hospital, University of Cape Town, King Khalid University, Washington State University, Tufts University

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funders: World Health Organization, National Institutes of Health, National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development

OpenAlex ID: W2906287133